SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-331369
Filing Date
2021-11-16
Accepted
2021-11-16 17:16:04
Documents
12
Period of Report
2021-11-12
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d368899d8k.htm   iXBRL 8-K 23271
  Complete submission text file 0001193125-21-331369.txt   145057

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA avir-20211112.xsd EX-101.SCH 2898
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE avir-20211112_lab.xml EX-101.LAB 18123
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avir-20211112_pre.xml EX-101.PRE 11409
5 EXTRACTED XBRL INSTANCE DOCUMENT d368899d8k_htm.xml XML 3350
Mailing Address 125 SUMMER STREET 16TH FLOOR BOSTON MA 02110
Business Address 125 SUMMER STREET 16TH FLOOR BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Filer) CIK: 0001593899 (see all company filings)

IRS No.: 460574869 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39661 | Film No.: 211417311
SIC: 2834 Pharmaceutical Preparations